Additionally, research to examine the newer and more potent weight-loss GLP-1 receptor agonists, semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly), would be particularly important.
Continued GLP-1 treatment or other approaches need to be part of the long-term strategy
All GLP-1 medications, whether brand-name or compounded, require a prescription from a licensed healthcare provider after a medical evaluation
Both have proven they can manufacture and distribute peptide therapies at scale
Multiple variables beyond the medication itself can significantly impact sexual health during tirzepatide treatment
The NIH ODS iron deficiency progression model explains that iron deficiency progresses from iron store depletion to iron-deficient erythropoiesis to IDA